1-8 of 8
Charles P. Hart
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

Jessica D. Sun, Qian Liu, Jingli Wang, Dharmendra Ahluwalia, Damien Ferraro, Yan Wang, Jian-Xin Duan, W. Steve Ammons, John G. Curd, Mark D. Matteucci, Charles P. Hart
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2287.
https://doi.org/10.1158/1078-0432.CCR-24-1058
Published: 15 May 2024
View article titled, Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Open the PDF for Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer in another window
Journal Articles

Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer

Rafael Duran, Sahar Mirpour, Vasily Pekurovsky, Shanmugasundaram Ganapathy-Kanniappan, Cory F. Brayton, Toby C. Cornish, Boris Gorodetski, Juvenal Reyes, Julius Chapiro, Rüdiger E. Schernthaner, Constantine Frangakis, MingDe Lin, Jessica D. Sun, Charles P. Hart, Jean-François Geschwind
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (2): 536–548.
https://doi.org/10.1158/1078-0432.CCR-16-0725
Published: 15 January 2017
View article titled, Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer
Open the PDF for Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer in another window
Includes: Supplementary data
Journal Articles

Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models

Juliana Benito, Marc S. Ramirez, Niki Zacharias Millward, Juliana Velez, Karine G. Harutyunyan, Hongbo Lu, Yue-xi Shi, Polina Matre, Rodrigo Jacamo, Helen Ma, Sergej Konoplev, Teresa McQueen, Andrei Volgin, Marina Protopopova, Hong Mu, Jaehyuk Lee, Pratip K. Bhattacharya, Joseph R. Marszalek, R. Eric Davis, James A. Bankson, Jorge E. Cortes, Charles P. Hart, Michael Andreeff, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1687–1698.
https://doi.org/10.1158/1078-0432.CCR-14-3378
Published: 31 March 2016
View article titled, Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
Open the PDF for Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models in another window
Includes: Supplementary data
Journal Articles

Abstract A22: Hypoxia-dependent antitumor activity of TH-302, a hypoxia-activated prodrug, in preclinical pancreatic xenograft models

Jessica D. Sun, Qian Liu, Dharmendra Ahluwalia, Yan Wang, Fanying Meng, Deepthi Bhupathi, John G. Curd, Mark D. Matteucci, Charles P. Hart
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): A22.
https://doi.org/10.1158/1078-0432.TCMUSA10-A22
Published: 02 February 2016
View article titled, Abstract A22: Hypoxia-dependent antitumor activity of TH-302, a hypoxia-activated prodrug, in preclinical pancreatic xenograft models
Journal Articles

Abstract A42: Antiangiogenic-induced increase in tumor hypoxia in RCC and NSCLC human tumor xenografts and its selective targeting by the hypoxia-activated prodrug TH-302: A model for clinical exploration?

Charles P. Hart, Dharmendra Ahluwalia, Qian Liu, Fanying Meng, Deepthi Bhupathi, John G. Curd, Mark D. Matteucci
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): A42.
https://doi.org/10.1158/1078-0432.TCMUSA10-A42
Published: 02 February 2016
View article titled, Abstract A42: Antiangiogenic-induced increase in tumor hypoxia in RCC and NSCLC human tumor xenografts and its selective targeting by the hypoxia-activated prodrug TH-302: A model for clinical exploration?
Journal Articles

TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging

Sarah G.J.A. Peeters, Catharina M.L. Zegers, Rianne Biemans, Natasja G. Lieuwes, Ruud G.P.M. van Stiphout, Ala Yaromina, Jessica D. Sun, Charles P. Hart, Albert D. Windhorst, Wouter van Elmpt, Ludwig J. Dubois, Philippe Lambin
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (13): 2984–2992.
https://doi.org/10.1158/1078-0432.CCR-15-0018
Published: 30 June 2015
View article titled, TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [<sup>18</sup>F]HX4 Hypoxia PET Imaging
Open the PDF for TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [<sup>18</sup>F]HX4 Hypoxia PET Imaging in another window
Includes: Supplementary data
Journal Articles

Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models

Scott Portwood, Deepika Lal, Yung-Chun Hsu, Rodrigo Vargas, Megan K. Johnson, Meir Wetzler, Charles P. Hart, Eunice S. Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (23): 6506–6519.
https://doi.org/10.1158/1078-0432.CCR-13-0674
Published: 01 December 2013
View article titled, Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
Open the PDF for Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models in another window
Includes: Supplementary data
Journal Articles

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

Jessica D. Sun, Qian Liu, Jingli Wang, Dharmendra Ahluwalia, Damien Ferraro, Yan Wang, Jian-Xin Duan, W. Steve Ammons, John G. Curd, Mark D. Matteucci, Charles P. Hart
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3): 758–770.
https://doi.org/10.1158/1078-0432.CCR-11-1980
Published: 01 February 2012
View article titled, Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Open the PDF for Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer in another window
Includes: Supplementary data